Efica® 960 EC Česká republika - čeština - Adama

efica® 960 ec

adama - emulgovatelný koncentrát - s-metolachlor - herbicidy

Kendo® 5 CS Česká republika - čeština - Adama

kendo® 5 cs

adama - suspenze kapsulí - lambda-cyhalotrin - insekticidy

Mirador® Uni Česká republika - čeština - Adama

mirador® uni

adama - suspenzní koncentrát - azoxystrobin + difenoconazole - fungicidy

Mirage® C Česká republika - čeština - Adama

mirage® c

adama - ve vodě dispergovatelné granule - cyprodinil - fungicidy

Response® Česká republika - čeština - Adama

response®

adama - ve vodě dispergovatelné granule - pyroxsulam - herbicidy

Breyanzi Evropská unie - čeština - EMA (European Medicines Agency)

breyanzi

bristol-myers squibb pharma eeig - cd19-directed genetically modified autologous cell-based product consisting of purified cd8+ t-cells (cd8+ cells), cd19-directed genetically modified autologous cell-based product consisting of purified cd4+ t cells (cd4+ cells) - lymphoma, large b-cell, diffuse; lymphoma, follicular; mediastinal neoplasms - antineoplastická činidla - breyanzi is indicated for the treatment of adult patients with diffuse large b-cell lymphoma (dlbcl), high grade b-cell lymphoma (hgbcl), primary mediastinal large b-cell lymphoma (pmbcl) and follicular lymphoma grade 3b (fl3b), who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy.

Carvykti Evropská unie - čeština - EMA (European Medicines Agency)

carvykti

janssen-cilag international nv - ciltacabtagene autoleucel - mnohočetný myelom - carvykti is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.

Cevenfacta Evropská unie - čeština - EMA (European Medicines Agency)

cevenfacta

laboratoire francais du fractionnement et des biotechnologies - eptacog beta (activated) - hemophilia a; hemophilia b - antihemoragika - cevenfacta is indicated in adults and adolescents (12 years of age and older) for the treatment of bleeding episodes and for the prevention of bleeding in those undergoing surgery or invasive procedures in the following patient groups:in patients with congenital haemophilia with high-responding inhibitors to coagulation factors viii or ix (i. ≥5 bethesda units (bu)); in patients with congenital haemophilia with low titre inhibitors (bu.

Qdenga Evropská unie - čeština - EMA (European Medicines Agency)

qdenga

takeda gmbh - dengue virus, serotype 2, expressing dengue virus, serotype 1, surface proteins, live, attenuated, dengue virus, serotype 2, expressing dengue virus, serotype 3, surface proteins, live, attenuated, dengue virus, serotype 2, expressing dengue virus, serotype 4, surface proteins, live, attenuated, dengue virus, serotype 2, live, attenuated - dengue - vakcíny - qdenga is indicated for the prevention of dengue disease in individuals from 4 years of age. the use of qdenga should be in accordance with official recommendations.

AFONILUM SR 125MG Tvrdá tobolka s prodlouženým uvolňováním Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

afonilum sr 125mg tvrdá tobolka s prodlouženým uvolňováním

viatris healthcare limited, dublin array - 4992 theofylin - tvrdá tobolka s prodlouženým uvolňováním - 125mg - theofylin